Compare Illumina, Inc. (ILMN) vs Snap Inc (SNAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Snap Inc — how do they compare? Illumina, Inc. trades at $270.52 (market cap $39.95B), while Snap Inc trades at $6.27 (market cap $9.83B). The key difference: Illumina, Inc. is far larger — about 4.1× Snap Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Snap Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Snap Inc for 68 Days on average.
| ILMN | SNAP | |
|---|---|---|
Market Cap | $39.95B | $9.83B |
Volume | 3,169,503 | 28,532,342 |
Sector | Health | Media |
52-Week High | $293.69 | $9.09 |
52-Week Low | $91.00 | $3.93 |
Typical Hold Time | 83 Days | 68 Days |
Enterprise Value | $41.31B | $11.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
Snap Inc. (SNAP) trades at $6.235, up 7.31% on the day, with a bullish technical signal from moving averages but a neutral oscillator stance. Revenue growth is steady, reaching $5.93B in 2025, though the company remains unprofitable with a net income margin of -4.9%. Recent news highlights AI and AR developments, including partnerships with NVIDIA and Salesforce for its SPECS glasses, driving positive sentiment despite regulatory pressures.
The stock presents a speculative opportunity with analyst consensus pointing to a $7.78 price target, but risks include persistent losses, high debt, and intense competition. Upside hinges on monetizing new AI/AR initiatives, while downside protection is limited by weak profitability and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Snap Inc
Snap, which refers to itself as a camera company, has one of the most popular social networking apps, Snapchat, in developed regions such as North America and Europe. The firm has approximately 158 million daily active users. Snap generates nearly all of its revenue from advertising with 88% coming from the U.S. The firm is headquartered in Venice, California.
Read more on SNAP →
